Lupin net profit up 40 per cent in Q4

Pharmaceutical company Lupin Ltd today on Wednesday posted a growth of 40.18 per cent in net profit at Rs220.62 crore for the fourth quarter ended 31 March over the same period a year ago.

Total income rose to Rs1,338.6 crore for the quarter, from Rs1,069 crore over the same period last year, Lupin said in a filing to the Bombay Stock Exchange.

The company's board of directors has proposed a dividend of Rs13.50 per equity share of face value of Rs10 each to the shareholders of the company.

Shares of the drug firm reacted positively to the results and surged nearly five per cent on the BSE. "Lupin has had a very strong year where we have continued to outperform across business segments and markets," Lupin managing director Kamal K Sharma said.

Lupin's Japanese subsidiary Lyowa contributed to 11 per cent of the company's total revenues at Rs534 crore, registering growth of 21 per cent, the filing added.

For the year ended 31 March, Lupin has posted net profit of Rs681.6 crore, up 35.91 per cent over the year-ago period.

Lupin's South African subsidiary, Pharma Dynamics grew 57 per cent to Rs132 crore, it said.